MedTrace Logo

Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients

NCT00713921 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2018-09-11

No results posted yet for this study

Summary

Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke

Conditions

Interventions

DRUG

Fesoterodine Oral Product

After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Saint Thomas Health

    lead OTHER

Principal Investigators

  • Barry K Jarnagin, MD · Vanderbilt University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-15
Primary Completion
2014-01-17
Completion
2014-01-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00713921 on ClinicalTrials.gov